mannoseRUTIs: D Mannose for Prevention and Treatment of RUTIs

• Sponsor: IRCCS Policlinico S. Matteo (Other)
• Overall Status: Completed
• CT.gov ID: NCT03790254
• Collaborator: (none)
• Enrollment: 500
• Location: 1
• Actual Duration (Months): 107.8
• Patients Per Site Per Month: 4.6

Study Details

Study Description

Brief Summary

The aim of this review is to address clinical reliability, efficacy and safety of long-term treatment with oral D Mannose for the prevention of recurrent urinary tract infections (RUTIs) in females.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Urinary Tract Infections; Antibiotic Prophylaxis; Antibiotic Resistance	Other: systematic review

Detailed Description

A comprehensive systematic MEDLINE, Embase, Cochrane search was performed for English language reports published before December 2018 using the term "recurrent urinary tract infections and d mannose." We searched Medline, Embase, and the Cochrane Register of Controlled Trials since January 2010 to December 2018. Eligible studies did not include non-oral therapy, local (vaginal) treatment in women with RUTIs.

Study eligibility criteria- We identified eligible original articles. The heterogeneity of the available studies, their different rationale and aim, the assumption of d mannose for prophylaxis or treatment of recurrent UTIs need to be taken into account.

Study Design

• Study Type: Observational
• Actual Enrollment: 500 participants
• Observational Model: Other
• Time Perspective: Retrospective
• Official Title: Oral D Mannose in the Prevention and Treatment of Recurrent Urinary Tract Infections: a Systematic Review
• Actual Study Start Date: Jan 1, 2010
• Actual Primary Completion Date: Dec 20, 2018
• Actual Study Completion Date: Dec 25, 2018

Outcome Measures

Primary Outcome Measures

1. research literature data on d mannose for prevention and treatment of recurrent urinary tract infections. [January 2010-December 2018]

   literature search of the Medline, Embase, and Cochrane Library databases

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 90 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

recurrent urinary tract infections (RUTIs)

Exclusion Criteria:

Upper urinary tract infections, severe clinical symptoms, fever > 37,5 with lumbar pain

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Urology Department Fondazione IRCCS Policlinico San Matteo	Pavia		Italy	27100

Sponsors and Collaborators

• IRCCS Policlinico S. Matteo

Investigators

• Principal Investigator: Daniele Porru, MD, Fondazione IRCCS Policlinico San Matteo

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Daniele Porru, MD, IRCCS Policlinico S. Matteo
• ClinicalTrials.gov Identifier: NCT03790254
• Other Study ID Numbers: ReviewUTIs
• First Posted: Dec 31, 2018
• Last Update Posted: Dec 31, 2018
• Last Verified: Dec 1, 2018

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Daniele Porru, MD, IRCCS Policlinico S. Matteo: recurrent urinary tract infections; d mannose prophylaxis; antibiotic prophylaxis
• Additional relevant MeSH terms: Infections; Urinary Tract Infections; Recurrence

Study Results

No Results Posted as of Dec 31, 2018